{"entity":{"id":"blood","kind":"journal","name":"Blood","aka":["Blood (ASH)","src-blood"],"tldr":"Blood is the American Society of Hematology's flagship journal, covering leukaemia, lymphoma, myeloma and transplant biology and trials, plus the ASH annual meeting abstracts.","summary":"Blood appears weekly and publishes the science and phase 2 trials of blood cancers (venetoclax, CAR-T, bispecifics, MRD methods), the ASH abstract supplement each November, and 'How I Treat' expert reviews that shape practice. Hybrid access; articles free after 12 months. Sister titles are Blood Advances (open access) and Blood Neoplasia.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Blood_(journal)","links":[{"label":"ASH annual meeting","url":"https://www.hematology.org/meetings/annual-meeting"}],"tags":[],"related":["src-ash-annual"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Holds: Flagship of haematology: leukaemia, lymphoma and myeloma trials and biology; ASH abstracts. Access: Paywalled; abstracts free."],"publisher":"American Society of Hematology","url":"https://ashpublications.org/blood","issn":"0006-4971","scope":"haematology","access":"hybrid","founded":1946,"impactFactor":{"value":21,"year":2023,"source":"Clarivate Journal Citation Reports 2024 (2023 JIF)"},"matchNames":["Blood"],"society":"American Society of Hematology"},"route":"/journals/blood/","neighbours":{"collection":[{"id":"src-ash-annual","kind":"collection","name":"ASH Annual Meeting","route":"/collections/src-ash-annual/"}],"paper":[{"id":"paper-heuser-blood","kind":"paper","name":"2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party","route":"/key-papers/paper-heuser-blood/"},{"id":"paper-stock-blood","kind":"paper","name":"A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403","route":"/key-papers/paper-stock-blood/"},{"id":"paper-tam-blood","kind":"paper","name":"A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study","route":"/key-papers/paper-tam-blood/"},{"id":"paper-wattel-blood","kind":"paper","name":"A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Français des Myélodysplasies and European CMML Group","route":"/key-papers/paper-wattel-blood/"},{"id":"paper-zammarchi-blood","kind":"paper","name":"ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies","route":"/key-papers/paper-zammarchi-blood/"},{"id":"paper-aza-aml-001-dombret-blood-2015","kind":"paper","name":"AZA-AML-001: azacitidine versus conventional care in older patients with acute myeloid leukaemia and more than 30 percent blasts","route":"/key-papers/paper-aza-aml-001-dombret-blood-2015/"},{"id":"paper-rockstar-blood-2021","kind":"paper","name":"Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study","route":"/key-papers/paper-rockstar-blood-2021/"},{"id":"paper-rossi-richter-syndrome-blood-2018","kind":"paper","name":"Biology and treatment of Richter syndrome","route":"/key-papers/paper-rossi-richter-syndrome-blood-2018/"},{"id":"paper-bmt-ctn-0803-autologous-transplant-hiv-lymphoma-alvarnas-blood-2016","kind":"paper","name":"BMT CTN 0803/AMC 071: autologous haematopoietic cell transplantation for HIV-related lymphoma","route":"/key-papers/paper-bmt-ctn-0803-autologous-transplant-hiv-lymphoma-alvarnas-blood-2016/"},{"id":"paper-cd19-all-leukemia-blood-2015","kind":"paper","name":"CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","route":"/key-papers/paper-cd19-all-leukemia-blood-2015/"},{"id":"paper-hans-immunohistochemistry-cell-of-origin-dlbcl-blood-2004","kind":"paper","name":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","route":"/key-papers/paper-hans-immunohistochemistry-cell-of-origin-dlbcl-blood-2004/"},{"id":"paper-rosai-dorfman-destombes-consensus-recommendations-blood-2018","kind":"paper","name":"Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease","route":"/key-papers/paper-rosai-dorfman-destombes-consensus-recommendations-blood-2018/"},{"id":"paper-khorana-blood","kind":"paper","name":"Development and validation of a predictive model for chemotherapy-associated thrombosis","route":"/key-papers/paper-khorana-blood/"},{"id":"paper-eln-2022-aml-dohner-blood-2022","kind":"paper","name":"ELN 2022: diagnosis and management of acute myeloid leukaemia in adults","route":"/key-papers/paper-eln-2022-aml-dohner-blood-2022/"},{"id":"paper-enasidenib-idh2-stein-blood-2017","kind":"paper","name":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukaemia","route":"/key-papers/paper-enasidenib-idh2-stein-blood-2017/"},{"id":"paper-epcoritamab-dlbcl-blood-2025","kind":"paper","name":"Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial","route":"/key-papers/paper-epcoritamab-dlbcl-blood-2025/"},{"id":"paper-erdheim-chester-disease-consensus-recommendations-blood-2020","kind":"paper","name":"Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis and treatment in the molecular era","route":"/key-papers/paper-erdheim-chester-disease-consensus-recommendations-blood-2020/"},{"id":"paper-eln-apl-sanz-blood-2019","kind":"paper","name":"European LeukemiaNet recommendations for the management of acute promyelocytic leukaemia (2019 update)","route":"/key-papers/paper-eln-apl-sanz-blood-2019/"},{"id":"paper-cd19-multiple-myeloma-blood-2020","kind":"paper","name":"How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies","route":"/key-papers/paper-cd19-multiple-myeloma-blood-2020/"},{"id":"paper-study-0201-blood-2006","kind":"paper","name":"Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial","route":"/key-papers/paper-study-0201-blood-2006/"},{"id":"paper-raajit-rampal-blood-2014","kind":"paper","name":"Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis","route":"/key-papers/paper-raajit-rampal-blood-2014/"},{"id":"paper-brentuximab-vedotin-hodgkin-lymphoma-blood-2018","kind":"paper","name":"Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma","route":"/key-papers/paper-brentuximab-vedotin-hodgkin-lymphoma-blood-2018/"},{"id":"paper-icc-2022-arber-blood-2022","kind":"paper","name":"International Consensus Classification of myeloid neoplasms and acute leukaemias (2022)","route":"/key-papers/paper-icc-2022-arber-blood-2022/"},{"id":"paper-lch-iii-therapy-prolongation-multisystem-lch-blood-2013","kind":"paper","name":"LCH-III: therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis","route":"/key-papers/paper-lch-iii-therapy-prolongation-multisystem-lch-blood-2013/"},{"id":"paper-viardot-blood","kind":"paper","name":"Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma","route":"/key-papers/paper-viardot-blood/"},{"id":"paper-defibrotide-2005-01-blood-2016","kind":"paper","name":"Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure","route":"/key-papers/paper-defibrotide-2005-01-blood-2016/"},{"id":"paper-badalian-very-braf-mutations-lch-blood-2010","kind":"paper","name":"Recurrent BRAF mutations in Langerhans cell histiocytosis","route":"/key-papers/paper-badalian-very-braf-mutations-lch-blood-2010/"},{"id":"paper-emile-revised-classification-of-histiocytoses-blood-2016","kind":"paper","name":"Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages","route":"/key-papers/paper-emile-revised-classification-of-histiocytoses-blood-2016/"},{"id":"paper-olsen-mycosis-fungoides-staging-blood-2007","kind":"paper","name":"Revisions to the staging and classification of mycosis fungoides and Sezary syndrome (ISCL/EORTC)","route":"/key-papers/paper-olsen-mycosis-fungoides-staging-blood-2007/"},{"id":"paper-sparano-blood","kind":"paper","name":"Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma","route":"/key-papers/paper-sparano-blood/"},{"id":"paper-treon-blood","kind":"paper","name":"Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia","route":"/key-papers/paper-treon-blood/"},{"id":"paper-jan-burger-blood-2009","kind":"paper","name":"The microenvironment in mature B-cell malignancies: a target for new treatment strategies","route":"/key-papers/paper-jan-burger-blood-2009/"},{"id":"paper-jan-burger-blood-2015","kind":"paper","name":"Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib","route":"/key-papers/paper-jan-burger-blood-2015/"}],"person":[{"id":"alex-herrera","kind":"person","name":"Alex F. Herrera","route":"/people/alex-herrera/"},{"id":"andrew-wei","kind":"person","name":"Andrew H. Wei","route":"/people/andrew-wei/"},{"id":"ola-landgren","kind":"person","name":"C. Ola Landgren","route":"/people/ola-landgren/"},{"id":"cheryl-willman","kind":"person","name":"Cheryl L. Willman","route":"/people/cheryl-willman/"},{"id":"christiane-pott","kind":"person","name":"Christiane Pott","route":"/people/christiane-pott/"},{"id":"claire-harrison","kind":"person","name":"Claire Harrison","route":"/people/claire-harrison/"},{"id":"eytan-stein","kind":"person","name":"Eytan M. Stein","route":"/people/eytan-stein/"},{"id":"jeffrey-miller","kind":"person","name":"Jeffrey Miller","route":"/people/jeffrey-miller/"},{"id":"tao-cheng","kind":"person","name":"Tao Cheng","route":"/people/tao-cheng/"},{"id":"thomas-loughran","kind":"person","name":"Thomas P. Loughran Jr.","route":"/people/thomas-loughran/"}],"journal":[{"id":"blood-advances","kind":"journal","name":"Blood Advances","route":"/journals/blood-advances/"}],"institution":[{"id":"ash","kind":"institution","name":"American Society of Hematology","route":"/institutions/ash/"}]}}